Clinical Trials Browser

Phase 3 × Erlotinib Hydrochloride × Head & Neck × Clear all

NCT00402779 2020-04-21

Erlotinib Prevention of Oral Cancer (EPOC)

Phase 3 Completed

303 enrolled 11 charts

Carcinoma in Situ, Mouth Neoplasms

NCT00412217 2016-11-25

A Study of Erlotinib (Tarceva) in Participants With Resected Head and Neck Squamous Cell Cancer

Phase 3 Terminated

94 enrolled 6 charts

Head and Neck Neoplasms